The Life Sciences Division

The Life Sciences Division is an investment bank

  • TLSD research qualifies as an acceptable minor non-monetary benefit an exemption under the European Commission’s Delegated Directive of 7.4.2016:32.
  • Visit provider site at https://thelifesciencesdivision.com/
Login

Latest Content

covid-19-are-we-closing-in-on-the-end-game-24-02-2021
COVID-19: are we closing in on the end-game?

24 Feb 21

Premium
immupharma-the-life-sciences-division-s-dr-malik-says-shares-are-oversold-reiterating-buy-rating-18-02-2021
Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold' reiterating BUY rating

18 Feb 21

Premium
FDA Update: Lupuzor™ meeting paves the way for commencement of Phase III trial in H2 2021

ImmuPharma plc

  • 15 Feb 21
  • -
US licensing deal: Major Opportunity Within LupuzorTM Unlocked

ImmuPharma plc

  • 05 Dec 19
  • -
Biogen Update on Aducanumab Likely to have a Major Impact on Sector re-rating, with Strong Read Across for LupuzorTM

ImmuPharma plc

  • 23 Oct 19
  • -
Interims 1H19: Unlocking Value in the Pipeline

ImmuPharma plc

  • 30 Sep 19
  • -
 

The Life Sciences Division Research and Daily Commentaries

Research Tree offers The Life Sciences Division research, providing ongoing coverage of 4 shares. We offer 14 reports from The Life Sciences Division on Research Tree.

  • Research reports provided by The Life Sciences Division

  • Companies covered by The Life Sciences Division

  • Sectors covered by The Life Sciences Division